2seventy bio News

EU to Require Additional Cancer Risk Labeling on CAR T Therapies

Seeking AlphaJun 14 15:55 ET

Express News | 2Seventy Bio Inc : Goldman Sachs Cuts Target Price to $2 From $5

ReutersJun 7 09:40 ET

Top Midday Decliners

Sprinklr (CXM) shares sank 16% after the company lowered its revenue outlook amid better-than-expected Q1 performance. Barclays cut its price target to $11 from $17 while maintaining its overweight ra

MT NewswiresJun 6 14:13 ET

Goldman Cuts 2seventy Bio to Neutral, Cites Competition Concerns

Seeking AlphaJun 6 10:47 ET

Goldman Sachs Downgrades 2seventy Bio(TSVT.US) to Sell Rating, Cuts Target Price to $2

Goldman Sachs analyst Salveen Richter downgrades $2seventy bio(TSVT.US)$ to a sell rating, and adjusts the target price from $5 to $2.According to TipRanks data, the analyst has a success rate of 47.1

moomoo NewsJun 6 05:31 ET

2seventy Bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (NASDAQ:TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO

BusinesswireMay 23 07:00 ET

Buy Rating Affirmed for 2seventy Bio on Strong Growth Prospects and Financial Stability

TipRanksMay 10 01:33 ET

2seventy bio | 10-Q: Quarterly report

SEC announcementMay 9 16:10 ET · Announcements

2seventy Bio Is Maintained at Buy by Canaccord Genuity

2seventy Bio Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 9 15:18 ET

Express News | Canaccord Genuity Maintains Buy on 2seventy Bio, Lowers Price Target to $11

BenzingaMay 9 15:08 ET

2seventy Bio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 147.19% Canaccord Genuity $12 → $11 Maintains Buy 04/08/2024 169.66% Citigroup $9 → $12 Maintai

BenzingaMay 9 15:06 ET

2seventy Bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 9 13:21 ET

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), 2seventy Bio (TSVT) and Marinus (MRNS)

TipRanksMay 9 07:01 ET

2seventy Bio Inc (TSVT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and ...

Yahoo FinanceMay 9 03:06 ET

Q1 2024 2Seventy Bio Inc Earnings Call

Yahoo FinanceMay 8 22:23 ET

2seventy Bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 8 15:15 ET

2seventy Bio Inc (TSVT) Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Realignments

Yahoo FinanceMay 8 08:39 ET

2seventy Bio Q1 Adj $(0.81), Inline, Sales $12.44M Miss $14.08M Estimate

2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(1.08) per share from the same period

BenzingaMay 8 07:08 ET

Express News | 2Seventy Bio Inc Q1 Shr View $-0.81 -- Lseg Ibes Data

ReutersMay 8 07:05 ET

Express News | 2Seventy Bio Inc - Qtrly Net Loss per Share - Basic and Diluted $1.01

ReutersMay 8 07:05 ET